Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DOV 216303

Drug Profile

DOV 216303

Alternative Names: DOV 216,303

Latest Information Update: 21 Apr 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer DOV Pharmaceutical
  • Class Antidepressants; Chlorobenzenes; Pyrrolidines; Small molecules
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 07 Dec 2006 Merck and DOV Pharmacueticals terminate their licensing agreement for DOV 216303; DOV regains all rights
  • 05 Oct 2005 Data from a media release have been added to the adverse events and Affective disorders therapeutic trials sections
  • 09 Aug 2004 Merck licensed the exclusive worldwide rights to DOV 216303 for the treatment of depression, anxiety and addiction
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top